Yong Peng

发表

CT-721, a Potent Bcr-Abl Inhibitor, Exhibits Excellent In Vitro and In Vivo Efficacy in the Treatment of Chronic Myeloid Leukemia

Ying Sun, De-guang Sun, Huan Wang, 2017, Journal of Cancer.

CT-707, a Novel FAK Inhibitor, Synergizes with Cabozantinib to Suppress Hepatocellular Carcinoma by Blocking Cabozantinib-Induced FAK Activation

Qiaojun He, Bo Yang, Ji Cao, 2016, Molecular Cancer Therapeutics.

Immune Cell-Derived Extracellular Vesicles – New Strategies in Cancer Immunotherapy

Yumin Yang, Xingjian Cao, Ying Chen, 2021, Frontiers in Immunology.

Multikinase Inhibitor CT-707 Targets Liver Cancer by Interrupting the Hypoxia-Activated IGF-1R-YAP Axis.

Qiaojun He, Bo Yang, Ji Cao, 2018, Cancer research.